New treatment of hpylori
Reading File
Finding Sources
Searching PubMed
"Helicobacter pylori" AND eradication AND treatment
Searching the Web
H pylori new treatment regimens 2025 guidelines vonoprazan rifabutin
Finding Sources
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC12708901
Here is a current, evidence-based overview of H. pylori treatment as of 2025-2026, based on the 2024 ACG Clinical Guideline (Chey et al., Am J Gastroenterol 2024;119:1730) and recent literature.
H. pylori Treatment: Current Evidence and New Regimens
Key Shift: Away from Standard Triple Therapy
PPI + clarithromycin + amoxicillin ("standard triple therapy") is no longer recommended empirically due to clarithromycin resistance rates exceeding 15% in most regions. The 2024 ACG guideline formally retired it as a default first-line option unless clarithromycin susceptibility is confirmed.
First-Line Regimens for Treatment-Naive Patients (All for 14 days)
1. Optimized Bismuth Quadruple Therapy (BQT) - PREFERRED
STRONG recommendation (moderate quality evidence)
| Drug | Dose | Frequency |
|---|---|---|
| PPI (standard dose) | e.g. omeprazole 20 mg | b.i.d. |
| Bismuth subcitrate or subsalicylate | 120-300 mg / 300 mg | q.i.d. |
| Tetracycline | 500 mg | q.i.d. |
| Metronidazole | 500 mg | t.i.d. or q.i.d. |
- Available as the combination pill Pylera (bismuth + metronidazole + tetracycline) + a PPI
- Also recommended for patients with penicillin allergy
- Achieves eradication rates >85-90%
2. Rifabutin Triple Therapy (Talicia) - NEW FDA-APPROVED OPTION
CONDITIONAL recommendation (low quality evidence)
| Drug | Dose | Frequency |
|---|---|---|
| Omeprazole | 10 mg (4 capsules = 40 mg total) | t.i.d. |
| Amoxicillin | 250 mg (per capsule) | t.i.d. |
| Rifabutin | 12.5 mg (per capsule) | t.i.d. |
- Talicia (omeprazole + amoxicillin + rifabutin) received FDA approval in 2019 - the first new H. pylori drug approved in 20+ years
- Rifabutin inhibits bacterial RNA polymerase; very low resistance rates
- Eradication rate ~83-90% in adherent patients (vs ~58-65% in non-adherent)
- Historically a rescue option, now listed as an empiric first-line alternative
- Risk of myelosuppression with rifabutin requires monitoring
3. PCAB-Based Regimens (Vonoprazan) - MAJOR NEW ADDITION
CONDITIONAL recommendation (moderate quality evidence)
Vonoprazan is a potassium-competitive acid blocker (P-CAB) - a new class of acid suppressant that works faster, achieves higher intragastric pH, and is less affected by CYP2C19 polymorphism compared to PPIs. This dramatically improves antibiotic efficacy.
a) PCAB Dual Therapy (Voquezna DualPak)
| Drug | Dose | Frequency |
|---|---|---|
| Vonoprazan | 20 mg | b.i.d. |
| Amoxicillin | 1000 mg | t.i.d. |
- Eradication rates >90% per protocol, especially in Asia
- Fewer adverse effects than BQT
- Approved by FDA; simpler regimen
b) PCAB Triple Therapy (Voquezna TriplePak)
| Drug | Dose | Frequency |
|---|---|---|
| Vonoprazan | 20 mg | b.i.d. |
| Clarithromycin | 500 mg | b.i.d. |
| Amoxicillin | 1000 mg | b.i.d. |
- Phase 3 RCTs showed superiority over lansoprazole-based triple therapy for clarithromycin-resistant strains
- Particularly useful when clarithromycin susceptibility is known or likely
Both Voquezna packs received FDA approval in 2022 (Phathom Pharmaceuticals).
Salvage / Second-Line Regimens (Treatment-Experienced Patients)
Antibiotic susceptibility testing is strongly recommended before choosing a salvage regimen. Options include:
| Situation | Recommended Regimen |
|---|---|
| Clarithromycin + levofloxacin sensitive | Triple (clarithro or levofloxacin) OR BQT OR rifabutin triple |
| Clarithromycin resistant, levofloxacin sensitive | BQT, rifabutin triple, or levofloxacin triple (PPI + levofloxacin + amoxicillin) |
| Both resistant | BQT or rifabutin triple |
Levofloxacin triple (PPI + levofloxacin 500 mg + amoxicillin 1000 mg, b.i.d. x 14 days) remains a widely used rescue regimen.
Emerging/Investigational Approaches
- Tailored/susceptibility-guided BQT: Selecting the antibiotic component based on fecal molecular susceptibility testing (e.g., clarithromycin vs. furazolidone) - shown to improve eradication rates in multicenter RCTs
- Probiotics as adjuncts: Saccharomyces boulardii added to vonoprazan dual therapy reduced adverse effects and may improve adherence
- Phage therapy: Bacteriophages targeting H. pylori under preclinical investigation
- Nanotherapy: Nanoparticle antibiotic delivery to improve gastric mucosal penetration
- H. pylori vaccines: Under active development; candidate antigens include urease, CagA, VacA, OipA - reviewed in Yunle et al., Helicobacter 2024 (PMID 37971157)
Cancer Prevention Note
A 2025 systematic review and meta-analysis in Gastroenterology (Ford et al., PMID 39824392) confirmed that H. pylori eradication significantly reduces gastric cancer risk in infected individuals, reinforcing the importance of treating all confirmed infections regardless of symptoms.
Practical Guidance Summary
| Priority | Regimen | Duration |
|---|---|---|
| First choice | Optimized BQT | 14 days |
| Alternative (no penicillin allergy) | PCAB dual or triple (vonoprazan-based) | 14 days |
| Alternative (FDA-approved kit) | Rifabutin triple (Talicia) | 14 days |
| Avoid empirically | Standard PPI-clarithromycin triple therapy | - |
| Salvage | Based on susceptibility testing | 14 days |
Always confirm eradication with urea breath test or stool antigen test at least 4 weeks after completing therapy (and 2 weeks after stopping PPI).
This is a shared conversation. Sign in to Orris to start your own chat.